文献速递MDS 与骨髓增殖性肿瘤白血病

阿扎胞苷直接调节骨髓间充质基质细胞区室增强健康造血

Direct modulation of the bone marrow mesenchymal stromal cell compartment by azacitidine enhances healthy hematopoiesis.
PubMed 文献 · Blood Adv · 2018-01-01

研究比较了骨髓增生异常综合征(MDS)患者与年龄匹配健康对照的体外扩增间充质基质细胞(MSC),经去甲基化药物阿扎胞苷(AZA)直接处理后,AZA 对健康及 MDS 来源 MSC 均产生直接效应,使其在共培养中支持健康而非恶性克隆性造血干/祖细胞(HSPC)扩增;RNA 测序鉴定出 AZA 调控的基质网络,包括细胞外基质分子(含胶原)和干扰素通路成分。

要点

  • AZA 直接作用于健康及 MDS 来源 MSC,使其在共培养中偏向支持健康而非恶性克隆性 HSPC 扩增。
  • RNA 测序鉴定出 AZA 调控的基质网络,主要涉及细胞外基质分子(含胶原)和干扰素通路成分。
  • 研究证明 AZA 的抗白血病活性部分通过直接作用于支持 HSPC 的骨髓龛实现,为表观遗传治疗病变 MSC 提供概念验证。

核心结论

  • 去甲基化药物 AZA 部分通过直接作用于支持 HSPC 的骨髓龛发挥抗白血病活性,为表观遗传治疗病变 MSC 提供概念验证。

研究设计与样本

  • 体外研究:比较 MDS 患者与年龄匹配健康对照的体外扩增 MSC,经 AZA 直接处理后检测其生长、分化及支持 HSPC 的能力。

主要发现

  • AZA 对健康及 MDS 来源 MSC 均产生直接效应,使其在共培养中支持健康而非恶性克隆性 HSPC 扩增。
  • RNA 测序分析鉴定出 AZA 调控的基质网络,包括细胞外基质分子(含胶原)和干扰素通路成分等对 HSPC 支持关键的分子通路。

临床怎么用

  • 作者认为 AZA 敏感基因网络的综合数据集可作为框架,指导未来针对 MDS 和急性髓系白血病等髓系恶性肿瘤的靶向表观遗传龛治疗开发。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mesenchymal stromal cells (MSCs) are crucial components of the bone marrow (BM) microenvironment essential for regulating self-renewal, survival, and differentiation of hematopoietic stem/progenitor cells (HSPCs) in the stem cell niche. MSCs are functionally altered in myelodysplastic syndromes (MDS) and exhibit an altered methylome compared with MSCs from healthy controls, thus contributing to disease progression. To determine whether MSCs are amenable to epigenetic therapy and if this affects their function, we examined growth, differentiation, and HSPC-supporting capacity of ex vivo-expanded MSCs from MDS patients in comparison with age-matched healthy controls after direct treatment in vitro with the hypomethylating agent azacitidine (AZA). Strikingly, we find that AZA exerts a direct effect on healthy as well as MDS-derived MSCs such that they favor support of healthy over malignant clonal HSPC expansion in coculture experiments. RNA-sequencing analyses of MSCs identified stromal networks regulated by AZA. Notably, these comprise distinct molecular pathways crucial for HSPC support, foremost extracellular matrix molecules (including collagens) and interferon pathway components. Our study demonstrates that the hypomethylating agent AZA exerts its antileukemic activity in part through a direct effect on the HSPC-supporting BM niche and provides proof of concept for the therapeutic potential of epigenetic treatment of diseased MSCs. In addition, our comprehensive data set of AZA-sensitive gene networks represents a valuable framework to guide future development of targeted epigenetic niche therapy in myeloid malignancies such as MDS and acute myeloid leukemia.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Wenk C, Garz AK, Grath S, et al. Direct modulation of the bone marrow mesenchymal stromal cell compartment by azacitidine enhances healthy hematopoiesis. Blood Adv. 2018. PMID: 30518537. doi:10.1182/bloodadvances.2018022053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。